TMPO and non-small cell lung carcinoma: LINC00996, RPARP‐AS1, SND1‐IT1, and TMPO‐AS1 have emerged as key molecules in the intricate network of tumour pathophysiology, potentially influencing NSCLC progression and patient outcomes.